(IN BRIEF) Sanofi and CD&R have entered exclusive negotiations for CD&R to acquire a 50% controlling stake in Opella, Sanofi’s consumer healthcare business, while Sanofi retains a significant share. The partnership aims to support Opella’s growth as a global leader … Read the full press release
Posted in Business, Environment, Financial, France, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged acquisition, Allegra, CDR, Doliprane, expansion, France, Healthcare, Julie Van Ongevalle, Opella, partnership, Paul Hudson, Sanofi
(IN BRIEF) Sanofi and Orano Med have partnered to accelerate the development of next-generation radioligand therapies (RLTs) for rare cancers. By combining their expertise, they aim to advance treatments using lead-212 (212Pb) alpha-emitting isotopes, which target and destroy cancer cells … Read the full press release
Posted in Business, Environment, Financial, France, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged Cancer Therapies, Nicolas Maes, Orano Med, partnership, Paul Hudson, radioligand therapies (RLTs), rare cancers, safety, Sanofi, sustainability, USA
(IN BRIEF) Sanofi is showcasing its ambitious pipeline transformation strategy, which includes a record 12 potential blockbuster opportunities currently under clinical evaluation. Among these, there are nine innovative medicines and vaccines with peak sales potential ranging from €2 to €5 … Read the full press release
Posted in Business, France, Healthcare, Industrial, Management, Media, News, Pharma & Biotech, Science, Technology
Tagged Houman Ashrafian, Immunology Industry, Paul Hudson, Sanofi
(IN BRIEF) Sanofi and Teva Pharmaceuticals have announced a collaboration to co-develop and co-commercialize TEV’574, a promising asset currently in Phase 2b clinical trials for the treatment of Ulcerative Colitis and Crohn’s Disease, both forms of inflammatory bowel disease (IBD). … Read the full press release
Posted in Business, Environment, Financial, France, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science
Tagged Anti-TL1As, Crohn's disease, in $1.5 Billion Deal, Inflammatory Bowel Disease Treatment, partnership, Paul Hudson, Richard Francis, Sanofi, sustainability, Teva, TEV’574, Ulcerative colitis, wellness
(IN BRIEF) Meningitis Research Foundation, the Confederation of Meningitis Organisations (CoMO), and Sanofi have united to introduce ‘The Meningitis Flag,’ a worldwide campaign aimed at increasing awareness in the fight against meningitis. The campaign, supported by para-athletes including Ellie Challis, … Read the full press release
Posted in Business, Education, France, Healthcare, Management, Marketing, Media, News, Pharma & Biotech, Science, Sports
Tagged 'The Meningitis Flag', awareness, Confederation of Meningitis Organisations (CoMO), Davide Morana, Ellie Challis, Global Campaign, meningitis, Meningitis Research Foundation, Paris 2024 Paralympic Games, partnership, Paul Hudson, Sanofi, Théo Curin, vaccination, Vinny Smith
(NOTICIA EN BREVE) Sanofi ha nombrado a Elisabeth Moreno, exministra francesa de Igualdad de Género, Diversidad e Igualdad de Oportunidades, para su Junta de Diversidad, Equidad e Inclusión (DE&I) para los próximos tres años. El consejo asesor se creó en … Read the full press release
Posted in Business, France, Management, Pharma & Biotech
Tagged Caroline Casey, Dell, derechos humanos, diversidad, Dr. Rohini Anand, Elisabeth Moreno, Emmanuel Macron, France Télécom, Hewlett Packard, igualdad de género, Igualdad de oportunidades, Junta DE&I, Lenovo, lucha contra la discriminación, nombramiento, Paul Hudson, Sanofi
(IN BRIEF) Sanofi has appointed Elisabeth Moreno, former French Minister for Gender Equality, Diversity and Equal Opportunities, to its Diversity, Equity and Inclusion (DE&I) Board for the next three years. The advisory council was created in 2022 to support Sanofi’s … Read the full press release
Posted in Business, France, Management, Pharma & Biotech
Tagged appointment, Caroline Casey, DE&I Board, Dell, diversity, Dr. Rohini Anand, Elisabeth Moreno, Emmanuel Macron, Equal opportunities, fight discrimination, France Télécom, gender equality, Hewlett Packard, human rights, Lenovo, Paul Hudson, Sanofi
Accelerating projects on access to medicines, support for vulnerable communities, environmental conservation, and diversity and inclusion Creation of Sanofi Global Health, global nonprofit unit to provide 40 of the world’s poorest countries access to 30 essential medicines (PRESS RELEASE) PARIS, 7-Apr-2021 — … Read the full press release
Posted in France, Healthcare, News, Non Profit, Pharma & Biotech, Society
Tagged access to medicines, Cancer, cardiovascular disease, chronic diseases, climate change, Corporate Social Responsibility, CSR strategy, Diabetes, diversity, environmental protection program, Fabry, Gaucher, healthcare professionals, Inclusion, malaria, nonprofit unit, open letter, Paul Hudson, Pharmaceutical, Planet Mobilization, polio, Pompe diseases, preservation of the environment, rare diseases, Sanofi, Sanofi Global Health, sleeping sickness, support for vulnerable communities, tuberculosis, vaccines, WHO, World Health Organization, Zero plastic packaging
(PRESS RELEASE) PARIS/ CAMBRIDGE, 11-Jan-2021 — /EuropaWire/ — French multinational pharmaceutical company Sanofi to acquire Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics. The agreement includes an upfront payment … Read the full press release
Posted in France, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged acquisition, antibody for inflammatory disorders, antibody technologies, atopic dermatitis, biopharmaceutical, biopharmaceutical company, EASI, Eczema Area and Severity Index, fully human antibodies, Goodwin PLC, Gotshal & Manges LLP, human monoclonal antibodies, human monoclonal antibody, ICOS agonist monoclonal antibody, immune regulator, immune-mediated diseases, immuno-oncology therapeutics, inflammatory disorders, J.P. Morgan, John Reed M.D. Ph.D., KY1005, KY1044, Kymab, novel therapies, OX40-Ligand, OX40L, Paul Hudson, Sanofi, Simon Sturge, topical corticosteroids, Weil
Further strengthens core R&D areas of autoimmune and allergic diseases Provides full control of brain-penetrant BTK inhibitor SAR442168 in multiple sclerosis (MS), making commercialization more efficient and eliminating future royalty payments Allows expansion of SAR442168 development program into other central … Read the full press release
Posted in Business, France, Healthcare, Investment, News, Pharma & Biotech
Tagged acquisition, allergic diseases, Arnaud Delepine, Ashleigh Koss, autoimmune diseases, biopharmaceutical, BofA Securities, Bruton tyrosine kinase, BTK inhibitor, BTK inhibitor ‘168, Centerview Partners LLC, Christopher Chai, commercialization, Cooley LLP, Eva Schaefer-Jansen, Evercore, Fara Berkowitz, Felix Lauscher, Gotshal & Manges LLP, John Reed M.D. Ph.D., Martin Babler, MS, multiple sclerosis, Nicolas Kressmann, pathophysiology, Paul Hudson, Paul Laland, Pharmaceutical, Principia, Principia Biopharma, PRN473 Topical, rilzabrutinib, Sanofi, SAR442168, Suzanne Greco, Weil, Yvonne Naughton
Sanofi to provide Plaquenil® (hydroxychloroquine) wherever possible, while securing appropriate supply levels for current approved indications; The company already increased its production capacity by 50% and is on track to further increase production over the coming months; Ongoing global clinical … Read the full press release
Posted in France, Healthcare, News, Pharma & Biotech, Science, Society, Technology
Tagged coronavirus, COVID-19, donation, hydroxychloroquine, Paul Hudson, Plaquenil, Sanofi
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?
PHARMA & BIOTECH: The largest repository of EU/European pharma & biotech press releases spanning 12 years (2012-2024)
